US00974H1041 - Common Stock - After market: 12.33 0 (0%)
NASDAQ:AKYA (12/8/2022, 7:25:00 PM)+0.53 (+4.49%)
|GICS Sector||Health Care|
|GICS Industry||Life Sciences Tools & Services|
|Earnings (Last)||11-07 2022-11-07/amc||Earnings (Next)||03-13 2023-03-13|
|Ins Owners||4.36%||Inst Owners||37.6%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 149 full-time employees. The company went IPO on 2021-04-16. The firm deliveries spatial biology solutions, which is focused on transforming discovery and clinical research. Spatial biology technology enables academic and biopharma scientists to detect and map the distribution of cell types and biomarkers across whole tissue samples at single-cell resolution, enabling advancements in their understanding of disease progression and patient response to therapy. Through its PhenoCycler and PhenoImager platform, reagents, software and services, it offers end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research. The company provides PhenoImager HT, which is a digital pathology slide scanner featuring MOTiF whole-slide multispectral scanning of up to seven biomarkers with an 80-slide capacity. The company offers contract research services laboratory, which is called as advanced biopharma solutions.
AKOYA BIOSCIENCES INC
100 Campus Drive, 6Th Floor
CEO: Brian McKelligon
Q3 2022 revenue $18.9 million, 40% y/y growthRaising FY 2022 revenue guidance range to $73-75 million MARLBOROUGH, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE)...
MARLBOROUGH, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
Here you can normally see the latest stock twits on AKYA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.